Virtual Therapeutics To Acquire Akili For $34 Million   

Digital mental health provider Virtual Therapeutics plans to acquire publicly traded Akili, Inc., for $34 million, about 43.4 cents per share. Akili, Inc., provides the EndeavorRx digital therapeutic for attention-deficit/hyperactivity disorder (ADHD). The deal is expected to close in the third quarter of 2024, after which Akili will operate as wholly owned subsidiary of Virtual Therapeutics.

Akili's EndeavorRx digital therapeutic is cleared by the FDA to lessen ADHD symptoms only in children between the ages of 8 and 12. It is currently under review for other age groups. In April, Akili cut staff by about 46 . . .